Mental Health Consequences of COVID19 Infection in the French RMD Cohort

Terminated

• Conditions: Covid19; Auto Inflammatory Diseases; Systemic Autoimmune Disease; Inflammatory Rheumatism

• Registration Number: NCT04510467
• Lead Sponsor: University Hospital, Lille

Brief Summary

this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-08-11
• Study First Submitted QC: 2020-08-11
• Study First Posted: 2020-08-12
• Study Start: 2021-01-20
• Primary Completion: 2022-05-19
• Study Completion: 2022-05-19
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-11
• Last Update Posted: 2023-01-13

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 296

Inclusion Criteria

Patient case:

• Patient with inflammatory rheumatism, systemic autoimmune or autoimmune disease
• With confirmed COVID-19 infection (at least one month prior to study inclusion)
• Study information given to the patient
• Patient affiliated to social security

Patient control:

• Patient with inflammatory rheumatism, systemic autoimmune disease or autoimmune disease.
• Not having had a confirmed COVID-19 infection
• Study information given to the patient
• Patient affiliated to social security

Exclusion Criteria

• Opposition to participation in the study by the patient and/or his legal representative
• Adult patient not able to understand the implications and rules of the study
• Protected adults under guardianship or curatorship

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID	at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection

Secondary Outcome Measures

Name	Time	Method
Severity of PTSD depending on whether or not autoimmune patients have experienced COVID	at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection

Trial Locations

Locations (1)

Hop Claude Huriez Chu Lille; 🇫🇷 Lille, France